360ONE WAM Allots 2.13 Lakh Equity Shares Under Employee Stock Option Scheme

360ONE WAM Limited has allotted 2,12,637 equity shares of face value Re. 1 each to employees upon exercise of stock options under the company's Employee Stock Options Scheme, as announced on December 18, 2025. The allotment was approved by the Nomination and Remuneration Committee of the Board of Directors through a circular resolution passed on the same date.

Share Allotment Details

The equity shares were allotted under the company's employee stock option schemes, reflecting the organization's commitment to employee participation in equity ownership. The allotment represents a significant distribution of shares to eligible employees who exercised their stock options.

Parameter:	Details
Shares Allotted:	2,12,637 equity shares
Face Value:	Re. 1.00 per share
Allotment Date:	December 18, 2025
Approval Authority:	Nomination and Remuneration Committee
Scheme:	Employee Stock Options Scheme

Impact on Share Capital

Following this allotment, the company's issued, subscribed and paid-up share capital has increased substantially. The share capital structure demonstrates the company's growth in employee participation through equity ownership programs.

Capital Structure:	Before Allotment	After Allotment
Paid-up Capital:	₹40,50,57,728	₹40,52,70,365
Number of Shares:	40,50,57,728	40,52,70,365
Face Value per Share:	Re. 1.00	Re. 1.00

Regulatory Compliance

The company has informed both BSE Limited and National Stock Exchange of India Limited about this development in compliance with regulatory requirements under Regulation 30. The communication was signed by Rohit Bhase, Company Secretary (ACS: 21409), ensuring proper disclosure to all relevant stakeholders and maintaining transparency in corporate governance practices.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-4.63%	-2.18%	-4.00%	-3.53%	-2.11%	+77.00%

Cipla has announced the launch of Yurpeak (Tirzepatide), a new therapeutic treatment designed for patients suffering from obesity and Type 2 diabetes. This launch marks a significant addition to the company's pharmaceutical portfolio in the metabolic disorders segment.

Product Overview

Yurpeak contains Tirzepatide as its active pharmaceutical ingredient, targeting two major health conditions that affect millions of patients globally. The medication addresses both obesity management and Type 2 diabetes treatment, offering a dual therapeutic approach for patients dealing with these interconnected metabolic conditions.

Product Details:	Information
Product Name:	Yurpeak
Active Ingredient:	Tirzepatide
Therapeutic Areas:	Obesity and Type 2 Diabetes
Company:	Cipla

Market Significance

The launch of Yurpeak represents Cipla's strategic focus on expanding its presence in the diabetes and obesity treatment market. This therapeutic area continues to show significant demand due to the growing prevalence of metabolic disorders worldwide. The introduction of Tirzepatide-based treatment adds to the available options for healthcare providers treating patients with these conditions.

Company Portfolio Enhancement

With the addition of Yurpeak, Cipla strengthens its position in the metabolic disorders segment. The company continues to diversify its pharmaceutical offerings, focusing on therapeutic areas with substantial patient needs. This launch demonstrates the company's commitment to bringing innovative treatment solutions to the market for managing complex health conditions like obesity and diabetes.